查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861922

生物製药生物分离系统市场按产品类型、操作模式、材料类型、应用和最终用户划分 - 全球预测（2025-2030 年）

Biopharmaceutical Bioseparation Systems Market by Product Type, Operation Mode, Material Format, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2030 年，生物製药生物分离系统市场将成长至 243.8 亿美元，复合年增长率为 9.54%。

关键市场统计数据
基准年 2024 141亿美元
预计年份：2025年 154.2亿美元
预测年份 2030 243.8亿美元
复合年增长率 (%) 9.54%

展望未来，先进的生物分离系统将以其高效性、扩充性和合规性革新生物製药工作流程。

本执行摘要介绍了生物分离系统在现代生物製药生产中的现状和战略发展方向。下游纯化领域已从专注于孤立的宣传活动操作发展成为兼顾产量、纯度和操作灵活性的综合性学科。同时，业界正在采用更多模组化和一次性架构，以加快生产週期并降低资本投入，同时满足日益严格的产品品质和製程验证监管要求。因此，相关人员在重新评估长期以来在批次处理和连续处理灵活性之间的技术权衡，以适应日益多样化的分子类型和生产规模。

分析颠覆性创新和製程整合如何重新定义下游生物製造的产量、纯度和永续性

生物分离系统领域正经历着变革性的转变，这不仅重塑了技术蓝图，也改变了整个价值链的商业性行为。层析法介质的进步、膜技术的改进以及可靠的圆盘式和卧螺式离心平台的出现，正在突破技术的界限，实现高通量操作和更高效的杂质去除。同时，一次性技术正从小众应用领域走向核心生产过程和下游纯化步骤，从而减轻了多产品生产设施的清洁验证负担，并缩短了生产前置作业时间。这些变化并非纯粹的技术变革，而是反映了营运模式的重组，旨在提高灵活性、加速临床试验进程并降低专案层面的风险。

评估美国关税至2025年及其对生物製造领域采购、供应连续性和下游经济的影响

美国关税将于2025年之前生效，为全球生物分离供应链带来了显着的复杂性，其影响涵盖采购惯例到资本规划等各个方面。关税调整大幅提高了进口模组、备件和专用耗材的到岸成本，促使製造商重新评估其供应商选择标准、合约条款和库存策略。在需要单一来源组件来确保工艺流程检验的情况下，关税相关的成本波动正在加速关于双重采购、关键供应商近岸外包以及重新设计关键子系统以减少对受关税影响的进口产品的依赖等问题的讨论。

透过对产品类型、应用领域、最终用户和操作模式进行深度細項分析，指导生物分离领域的投资重点。

细分市场趋势分析揭示了不同产品类型、应用、最终用户和操作模式所带来的独特机会和限制因素，这些因素共同决定了投资重点和实施路径。产品系列涵盖离心、层析法、薄膜过滤和一次性系统。离心进一步细分为卧螺离心机、碟片式离心机和管式离心机，选择依据原料特性及澄清能力需求。层析法产品依模式分类，包括亲和性、疏水交互作用层析、离子交换层析、混合模式层析和尺寸排除层析。亲和亲和性产品包括一些特殊形式，例如固定化金属亲和性、凝集素亲和性和层析和蛋白A亲和性，这些产品针对特定的生物分子类别。膜过滤包含微过滤、奈米过滤和超过滤方法，选择依据孔径要求和通量目标。一次性系统涵盖一次性层析法和一次性过滤，可实现快速部署并降低多条产品线交叉污染的风险。

美洲、欧洲、中东、非洲和亚太地区的区域趋势将影响基础设施投资和跨境供应链策略。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的技术应用、监管合规和供应链配置产生了显着影响。在美洲，生物製药製造中心的集中布局和成熟的供应商生态系统支援了复杂多产品生产设施和连续生产流程的早期应用，而密集的服务供应商网路则有助于快速验证和试运行。在欧洲、中东和非洲地区，多样化的管理体制以及对品质和环境合规的高度重视，推动了对节能营运和下游加工先进废弃物管理的投资。在亚太地区，产能的快速扩张与优先考虑成本竞争力解决方案和可扩展的一次性部署的本地化製造倡议相结合，同时区域政策奖励正在推动生物製药及其配套基础设施的本土化生产。

企业趋势分析：生物分离供应商的伙伴关係、技术差异化、场地优化与竞争定位

生物分离供应商生态系统中的企业策略正在融合产品创新、服务拓展和商业性合作，以深化客户关係并减少实施过程中的阻力。领先的设备和耗材供应商正透过专有化学技术、先进的树脂技术和自动化能力实现差异化，同时投资于提供远端监控、预测性维护和生命週期分析的数位化平台。与契约製造、生物服务公司和仪器供应商建立策略合作伙伴关係，使供应商能够提供整合硬体、耗材和製程支援的承包解决方案，从而打造更具吸引力的商业性提案。这种解决方案化趋势降低了买方整合风险，并加快了复杂下游应用实现价值的速度。

旨在加快营运韧性、降低纯度成本并促进各层级模组化和连续生物分离技术应用的实用建议

产业领导者可以采取一系列切实可行的倡议，从不断发展的生物分离技术中获得营运和策略效益。首先，优先考虑资本投资的模组化，以便将新的层析法装置、膜分离系统和离心模组整合到现有系统中，最大限度地减少对检验流程和公用设施的影响。这种方法可以降低实施风险，并允许根据产品平臺需求分阶段进行现代化改造。其次，制定采购策略，透过寻找替代供应商、确保关键耗材的目标安全库存以及签订包含绩效指标和紧急条款的合作筹资策略协议，来平衡成本、前置作业时间和关税风险。这些措施将增强企业应对地缘政治和物流衝击的能力。

采用稳健的调查方法，结合针对性的初步访谈、技术文献综述和多面向资料检验，以检验产业趋势。

本报告的调查方法结合了针对技术领导者、工程师和采购专业人员的定向访谈、对技术文献和监管指南的系统性回顾，以及严谨的多源资料三角验证流程，以支援研究观察结果。主要研究旨在揭示实际实施中的挑战、供应商绩效特征以及供应链的实际调整，而次要分析则将这些发现与已发表的技术研究、供应商文件和公开的监管材料进行整合和背景分析。这种三角验证确保了关于技术能力和采用驱动因素的论点至少透过两个独立的证据来源得到检验。

简明扼要的结论，综合分析了技术转型、供应风险以及对推动生物分离领域营运转型的相关人员的策略影响。

总之，生物分离系统正处于转折点，技术创新、营运模式和地缘政治因素相互交织，重新定义下游製造策略。离心、层析法、薄膜过滤和一次性解决方案之间的相互作用，正在创造更丰富的架构选择；连续加工的兴起，迫使製造商重新思考生命週期成本、控制和供应链韧性。区域差异和关税趋势进一步要求在采购和场地设计方面采取更细緻入微的方法，而将技术差异化与服务和数位化能力相结合的供应商策略，将日益决定专案的成功执行。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 一次性层析法系统的兴起旨在减少交叉污染并提高生产灵活性。
  • 推出连续下游处理平台，可实现生物分离过程中的无缝整合和高通量处理。
  • 整合先进的製程分析技术，用于即时监测炼油过程和产品品质属性
  • 开发用于下一代单株抗体纯化的高容量、高选择性膜层析法
  • 应用数位双胞胎建模和人工智慧技术优化生物分离程式参数和产量
  • 采用模组化、可携式生物处理撬装设备可实现生物分离製程的快速规模化生产，并减少设施占地面积。
  • 更重视永续性，采用可再生层析法介质和环保清洗再生通讯协定
  • 新兴的蛋白A替代品和新型亲和性和配体可降低成本并提高病毒清除率
  • 单一途径切向流过滤技术的进步可提高生物製药生产中浓缩和过滤过程的效率
  • 监管机构强调品质源自于设计 (QbD) 框架，以确保生物製药纯化过程中的稳健控制策略。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 生物製药生物分离系统市场（依产品类型划分）

  • 离心分离系统
    • 卧螺离心机系统
    • 碟片式离心机系统
    • 管式碗离心机系统
  • 层析法系统
    • 亲和层析法
      • 固定化金属亲和层析法
      • 凝集素亲和层析法
      • 蛋白A亲和性和层析法
    • 疏水交互作用层析法
    • 离子交换层析法
    • 混合模式层析法
    • 尺寸排阻层析法
  • 薄膜过滤系统
    • 过滤系统
    • 奈米过滤系统
    • 超过滤系统

9. 生物製药生物分离系统市场（依操作模式划分）

  • 批量处理
  • 连续加工
    • 多柱层析法
    • 灌注治疗

第十章 生物製药生物分离系统市场（依材料类型划分）

  • 可重复使用类型
  • 一次使用
    • 伽玛射线辐照流道
    • 预灭菌组件

第十一章 生物製药生物分离系统市场（按应用划分）

  • 细胞澄清
  • 纯化/最终纯化
  • 蛋白质纯化
    • 酵素纯化
    • 单株抗体
    • 胜肽纯化
    • 重组蛋白纯化
  • 疫苗生产
  • 病毒纯化

第十二章 生物製药生物分离系统市场（依最终用户划分）

  • 学术和研究机构
  • 生物製药公司
  • 生物服务
  • 契约製造组织

第十三章 生物製药生物分离系统市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 生物製药生物分离系统市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国生物製药生物分离系统市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • Asahi Kasei Corporation
    • Bio-Rad Laboratories, Inc.
    • GEA Group Aktiengesellschaft
    • Merck KGaA
    • Tecan Trading AG
    • Sartorius AG
    • Shimadzu Corporation
    • Tosoh Bioscience LLC
    • Alfa Laval AB
Product Code: MRR-521BAA36EA6F

The Biopharmaceutical Bioseparation Systems Market is projected to grow by USD 24.38 billion at a CAGR of 9.54% by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 14.10 billion
Estimated Year [2025] USD 15.42 billion
Forecast Year [2030] USD 24.38 billion
CAGR (%) 9.54%

A forward-looking introduction to advanced bioseparation systems transforming biopharmaceutical workflows with efficiency, scalability, and regulatory alignment

This executive summary introduces the current state and strategic contours of bioseparation systems as they intersect with modern biopharmaceutical manufacturing. The downstream purification domain has matured from a focus on isolated unit operations to an integrated discipline that balances throughput, purity, and operational agility. In parallel, the industry is negotiating tighter regulatory expectations for product quality and process validation while adopting more modular and single-use architectures to accelerate campaign turnaround and lower capital intensity. Consequently, stakeholders are re-evaluating long-standing engineering trade-offs between batch flexibility and continuous processing to align with increasingly varied molecule types and production scales.

The introduction frames the central themes that recur across this report: technological convergence across centrifugation, chromatography, membrane filtration, and single-use modalities; shifting application demand driven by vaccines, monoclonal antibodies, and novel biologics; and an evolving competitive environment that places a premium on service integration, digital enablement, and supply resilience. By establishing this context, the report prepares operators, technology providers, and procurement leaders to interpret subsequent sections that detail segmentation insights, regional dynamics, tariff effects, and corporate strategies. The aim is to equip decision-makers with a concise synthesis of trends and practical lenses for evaluating capital projects, vendor selection, and process modernization initiatives.

Analysis of disruptive technological advancements and process integrations that redefine throughput, purity, and sustainability in downstream biomanufacturing

The landscape for bioseparation systems is experiencing transformative shifts that are reshaping both technology roadmaps and commercial behavior across the value chain. Advances in chromatographic media, higher-performing membranes, and more reliable disc and decanter centrifuge platforms have expanded the technical envelope, enabling higher throughput operations and more robust impurity clearance. Simultaneously, single-use technologies have migrated from niche applications into primary production and downstream polishing steps, reducing cleaning validation burdens and shortening lead times for multi-product facilities. These shifts are not purely technical; they reflect an operational reorientation toward flexibility, faster time-to-clinic, and lower program-level risk.

Equally important, process intensification trends-especially the move toward continuous processing and multi-column chromatography-are altering plant layouts and capital allocation decisions. Continuous frameworks promise steadier product quality and more efficient resin utilization, yet they demand stronger controls infrastructure and supply chain hygiene. In response, vendors and end users are co-developing integrated offerings that bundle equipment, consumables, and digital process control to reduce implementation complexity. Finally, digitalization is serving as an accelerant: real-time analytics, model-based control, and predictive maintenance are improving uptime and enabling lifecycle management of purification assets. Together, these changes create new strategic imperatives for technology adoption, training, and cross-functional alignment between process development and manufacturing operations.

Assessment of United States tariffs through 2025 and implications for sourcing, supply continuity, and downstream process economics in biomanufacturing

United States tariff measures enacted through 2025 have introduced a material layer of complexity for global bioseparation supply chains, with implications that extend from procurement practices to capital planning. Tariff adjustments have increased the effective landed cost of imported modules, spare parts, and specialized consumables, creating an imperative for manufacturers to reassess supplier selection criteria, contract terms, and inventory strategies. In contexts where single-source components are essential to validated processes, tariff-related cost volatility has accelerated conversations around dual sourcing, nearshoring of key suppliers, and redesign of critical subsystems to reduce dependency on tariff-impacted imports.

Operationally, the tariffs have elevated the importance of total cost of ownership analysis and of scenario planning for supply interruptions. Manufacturers are prioritizing supplier resilience and lead-time certainty, often accepting modestly higher component prices in exchange for assured delivery and technical support. In the capital projects domain, procurement teams are expanding pre-award scrutiny to include tariff exposure and logistics risk, while engineering groups evaluate alternative designs that permit the substitution of non-tariffed materials without compromising validation. On the vendor side, equipment suppliers are responding through revised commercial models, localization of manufacturing nodes, and strategic stock positioning to smooth customers' procurement cycles and to preserve service levels. Ultimately, tariffs have reinforced the strategic value of supply chain transparency, flexible sourcing networks, and collaborative contracting practices between equipment makers and biomanufacturers.

Deep segmentation insights that illuminate product types, application areas, end users, and operation modes to guide targeted investments in bioseparation

Segment-level dynamics reveal differentiated opportunities and constraints across product types, applications, end users, and operation modes that together shape investment priorities and adoption pathways. Product families span centrifugation systems, chromatography systems, membrane filtration systems, and single-use systems, with centrifugation further differentiated into decanter, disc stack, and tubular bowl platforms that are selected based on feedstock characteristics and clarifier capacity needs. Chromatography offerings split across affinity, hydrophobic interaction, ion exchange, mixed-mode, and size exclusion modalities, while affinity options include specialized formats such as immobilized metal affinity, lectin affinity, and Protein A affinity that target discrete biomolecule classes. Membrane filtration encompasses microfiltration, nanofiltration, and ultrafiltration approaches that are chosen according to pore-size requirements and throughput targets. Single-use systems extend across single-use chromatography and single-use filtration, which offer rapid deployment and reduced cross-contamination risk for multi-product lines.

Applications drive equipment choices in nuanced ways, with cell clarification, polishing and final purification, protein purification, vaccine production, and virus purification each imposing distinct performance and validation constraints. Within protein purification, subsegments like enzyme purification, monoclonal antibodies, peptide purification, and recombinant protein purification create divergent demands for resolution, capacity, and consumable lifetimes. End users span academic and research institutes, biopharmaceutical companies, bioservices, and contract manufacturing organizations, each bringing different volume profiles, regulatory rigor, and service expectations that inform vendor engagement models. Operation mode is another critical vector: batch processing remains the default for many legacy systems and small-batch production, whereas continuous processing-encompassing multi-column chromatography and perfusion processing-appeals to organizations seeking higher utilization and consistent product quality. When these segmentation layers are viewed together, they reveal that optimal technology selection is context-dependent and that vendors who can align modular product families with application-specific service offerings will have a competitive edge in meeting diverse customer needs.

Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific shaping infrastructure investment and cross-border supply strategies

Regional dynamics materially influence technology adoption, regulatory navigation, and supply chain configuration across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated centers of biologics manufacturing and a mature supplier ecosystem support complex multi-product facilities and early adoption of continuous processing, while a dense service-provider network facilitates rapid validation and commissioning. Europe, Middle East & Africa exhibit heterogeneous regulatory regimes and a strong emphasis on quality and environmental compliance, prompting investments in energy-efficient operations and advanced waste management for downstream processes. Asia-Pacific combines rapid capacity expansion with localized manufacturing initiatives that prioritize cost-competitive solutions and scalable single-use deployments, and regional policy incentives are encouraging in-country production of biologics and their supporting infrastructure.

These regional variations have operational consequences: procurement teams calibrate sourcing strategies to local trade conditions and logistical realities, process development groups tune validation strategies to local regulatory expectations, and corporate leaders balance centralized design standards with regional customization to meet site-specific requirements. Cross-border collaboration and knowledge transfer remain essential levers for multinational programs, and the most effective approaches marry global technical standards with locally optimized supply and service arrangements.

Corporate analysis highlighting partnerships, technology differentiation, footprint optimization, and competitive positioning among bioseparation vendors

Corporate strategies within the bioseparation vendor ecosystem reflect a blend of product innovation, services expansion, and commercial partnerships intended to deepen customer relationships and reduce implementation friction. Leading equipment and consumable providers are differentiating through proprietary chemistries, advanced resin technologies, and automation capabilities while also investing in digital platforms that offer remote monitoring, predictive maintenance, and lifecycle analytics. Strategic partnerships with contract manufacturers, bioservices firms, and instrumentation suppliers enable vendors to deliver turnkey solutions that bundle hardware, consumables, and process support into more attractive commercial propositions. This trend toward solutionization mitigates buyer integration risk and shortens time-to-value for complex downstream deployments.

In parallel, companies are optimizing manufacturing footprints to improve delivery timelines and to manage tariff exposure, and some are creating regional assembly hubs or local sourcing agreements to enhance responsiveness. Competitive positioning increasingly depends on the ability to offer end-to-end validation support, robust technical training programs, and flexible commercial models such as equipment-as-a-service or reagent subscription arrangements. The cumulative effect is a market where technical differentiation is necessary but insufficient; vendors must also demonstrate reliable supply chains, expert services, and pragmatic pathways for clients to migrate from legacy processes to intensified or single-use approaches.

Actionable recommendations to accelerate operational resilience, reduce cost-to-purity, and enable adoption of modular and continuous bioseparation across tiers

Industry leaders can pursue a set of pragmatic actions to realize operational and strategic benefits from evolving bioseparation technologies. First, prioritize modularity in capital investments so that new chromatographic skids, membrane trains, or centrifugation modules can be integrated with minimal disruption to validated flows and utilities. This approach reduces implementation risk and enables staged modernization aligned with product pipeline needs. Second, develop sourcing strategies that balance cost, lead time, and tariff exposure by qualifying alternate suppliers, holding targeted safety stocks for critical consumables, and negotiating collaborative supply agreements that include performance metrics and contingency clauses. These measures strengthen resilience against geopolitical and logistical shocks.

Third, accelerate capability building in digital process control and analytics to support intensified and continuous operations. Training programs that upskill operators and process engineers in model-based control and real-time release concepts will shorten the learning curve and preserve product quality during transitions. Fourth, adopt flexible commercial models with vendors-such as pay-per-use for single-use disposables or bundled service contracts-to align cash flow with utilization rates and to lower barriers to technology adoption. Finally, foster cross-functional governance between process development, manufacturing, regulatory affairs, and procurement to ensure that technical choices are economically sensible, regulatory-compliant, and operationally executable. These recommendations create a coherent roadmap for deploying advanced bioseparation capabilities while mitigating execution risk.

Robust research methodology combining targeted primary interviews, technical literature review, and multi-source data triangulation to validate industry trends

The research methodology underpinning this report combines targeted primary interviews with technical leaders, engineers, and procurement professionals, a structured review of technical literature and regulatory guidance, and a rigorous multi-source data triangulation process to corroborate observations. Primary engagements were designed to surface practical implementation challenges, vendor performance characteristics, and real-world supply chain adaptations, while secondary analysis synthesized published technical studies, supplier documentation, and publicly available regulatory materials to contextualize those findings. Triangulation ensured that claims about technology capabilities and adoption drivers were validated through at least two independent evidence streams.

Where appropriate, the methodology also included scenario analysis to explore the operational implications of tariff shifts and supply chain disruptions, and sensitivity checks to identify assumptions that materially affect strategic conclusions. The report acknowledges limitations related to proprietary performance data and rapidly evolving supplier roadmaps; therefore, readers should interpret vendor capability statements alongside the practical validation exercises described in the methodology. Transparency in method and selective use of corroborated primary evidence underpin the report's conclusions and recommendations.

Concise conclusion synthesizing strategic implications for stakeholders navigating technological change, supply risks, and operational transformation in bioseparation

In conclusion, bioseparation systems are at an inflection point in which technological advances, operational models, and geopolitical forces converge to redefine downstream manufacturing strategy. The interplay between centrifugation, chromatography, membrane filtration, and single-use solutions is producing richer architectural choices, and the rise of continuous processing is compelling manufacturers to rethink lifecycle costs, controls, and supply resilience. Regional differences and tariff dynamics further compel nuanced approaches to sourcing and footprint design, while vendor strategies that combine technical differentiation with services and digital capabilities will increasingly determine execution success.

For stakeholders, the practical takeaway is clear: align capital and procurement strategies with a prioritized set of technical objectives, invest in workforce capabilities to manage intensified processes, and pursue supplier relationships that embed risk mitigation and service depth. Doing so will enable organizations to capture the benefits of higher productivity, improved product quality, and faster program timelines while managing the operational complexities introduced by rapid technological and market change.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of single-use and disposable chromatography systems to reduce cross contamination and improve manufacturing flexibility
  • 5.2. Adoption of continuous downstream processing platforms for seamless integration and higher throughput in bioseparation
  • 5.3. Integration of advanced process analytical technology for real-time monitoring of purification and product quality attributes
  • 5.4. Development of high-capacity and selective membrane chromatography for next-generation monoclonal antibody purification
  • 5.5. Implementation of digital twin modeling and artificial intelligence for optimizing bioseparation process parameters and yields
  • 5.6. Shift toward modular and portable bioprocessing skids enabling rapid scale-up and facility footprint reduction in bioseparation
  • 5.7. Increasing focus on sustainability through recyclable chromatographic media and eco-friendly cleaning and regeneration protocols
  • 5.8. Emergence of protein A alternatives and novel affinity ligands to decrease costs and improve viral clearance efficiency
  • 5.9. Advancements in single-pass tangential flow filtration to streamline concentration and diafiltration steps in biologics manufacturing
  • 5.10. Regulatory emphasis on quality by design frameworks ensuring robust control strategies for biopharmaceutical purification processes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceutical Bioseparation Systems Market, by Product Type

  • 8.1. Centrifugation Systems
    • 8.1.1. Decanter Centrifuge Systems
    • 8.1.2. Disc Stack Centrifuge Systems
    • 8.1.3. Tubular Bowl Centrifuge Systems
  • 8.2. Chromatography Systems
    • 8.2.1. Affinity Chromatography
      • 8.2.1.1. Immobilized Metal Affinity Chromatography
      • 8.2.1.2. Lectin Affinity Chromatography
      • 8.2.1.3. Protein A Affinity Chromatography
    • 8.2.2. Hydrophobic Interaction Chromatography
    • 8.2.3. Ion Exchange Chromatography
    • 8.2.4. Mixed-Mode Chromatography
    • 8.2.5. Size Exclusion Chromatography
  • 8.3. Membrane Filtration Systems
    • 8.3.1. Microfiltration Systems
    • 8.3.2. Nanofiltration Systems
    • 8.3.3. Ultrafiltration Systems

9. Biopharmaceutical Bioseparation Systems Market, by Operation Mode

  • 9.1. Batch Processing
  • 9.2. Continuous Processing
    • 9.2.1. Multi-Column Chromatography
    • 9.2.2. Perfusion Processing

10. Biopharmaceutical Bioseparation Systems Market, by Material Format

  • 10.1. Multi-Use
  • 10.2. Single-Use
    • 10.2.1. Gamma-Irradiated Flow Paths
    • 10.2.2. Presterilized Assemblies

11. Biopharmaceutical Bioseparation Systems Market, by Application

  • 11.1. Cell Clarification
  • 11.2. Polishing & Final Purification
  • 11.3. Protein Purification
    • 11.3.1. Enzyme Purification
    • 11.3.2. Monoclonal Antibodies
    • 11.3.3. Peptide Purification
    • 11.3.4. Recombinant Protein Purification
  • 11.4. Vaccine Production
  • 11.5. Virus Purification

12. Biopharmaceutical Bioseparation Systems Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Biopharmaceutical Companies
  • 12.3. Bioservices
  • 12.4. Contract Manufacturing Organizations

13. Biopharmaceutical Bioseparation Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceutical Bioseparation Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceutical Bioseparation Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Agilent Technologies, Inc.
    • 16.3.3. Asahi Kasei Corporation
    • 16.3.4. Bio-Rad Laboratories, Inc.
    • 16.3.5. GEA Group Aktiengesellschaft
    • 16.3.6. Merck KGaA
    • 16.3.7. Tecan Trading AG
    • 16.3.8. Sartorius AG
    • 16.3.9. Shimadzu Corporation
    • 16.3.10. Tosoh Bioscience LLC
    • 16.3.11. Alfa Laval AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 3. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2024 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2024 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AFRICA BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASEAN BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. GCC BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. BRICS BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. G7 BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. NATO BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CENTRIFUGATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DECANTER CENTRIFUGE SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY DISC STACK CENTRIFUGE SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY TUBULAR BOWL CENTRIFUGE SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY LECTIN AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN A AFFINITY CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MIXED-MODE CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SIZE EXCLUSION CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MEMBRANE FILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MICROFILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY NANOFILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ULTRAFILTRATION SYSTEMS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY OPERATION MODE, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BATCH PROCESSING, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CONTINUOUS PROCESSING, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-COLUMN CHROMATOGRAPHY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PERFUSION PROCESSING, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MATERIAL FORMAT, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MULTI-USE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY SINGLE-USE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY GAMMA-IRRADIATED FLOW PATHS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PRESTERILIZED ASSEMBLIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY CELL CLARIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 181. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 183. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 185. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY POLISHING & FINAL PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 187. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, 2025-2030 (USD MILLION)
  • TABLE 189. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 191. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 193. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PROTEIN PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 195. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 197. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 199. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ENZYME PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 201. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 203. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 205. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 207. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 209. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 211. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY PEPTIDE PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 213. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 215. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 217. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY RECOMBINANT PROTEIN PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 221. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 223. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 225. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 227. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 229. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY VIRUS PURIFICATION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 231. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 233. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 235. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 237. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 239. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 241. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 243. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 245. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 247. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BIOPHARMACEUTICAL BIOSEPARATION SYSTEMS MARKET SIZE, BY BIOSERVICES, BY GROUP, 2025-2030 (USD MILLION